Background: MITF encodes an oncogenic lineage-specific transcription factor in which a germline mutation (MITF
Methods: Here, we compared the SUMOylation status of endogenous MITF by proximity ligation assay in melanocytes isolated from wild-type (n ¼ 3) or E318K (n ¼ 4) MITF donors. We also used a newly generated Mitf E318K knock-in (KI) mouse model to assess the role of Mitf E318K (n ¼ 7 to 13 mice per group) in tumor development in vivo and performed transcriptomic analysis of the tumors to identify the molecular mechanisms. Finally, using immortalized or normal melanocytes (wild-type or E318K MITF, n ¼ 2 per group), we assessed the role of MITF E318K on the induction of senescence mediated by BRAF V600E Microphthalmia-associated transcription factor (MITF) is a key transcription factor that plays a pivotal role in melanocytes and melanoma development. MITF is also involved in the implementation of the resistance to targeted or immunotherapy (1, 2) . Although the role of MITF was a matter of debate a few years ago, it appears now that melanoma cells are able to switch from a low-MITF to a high-MITF phenotype, thereby adapting to micro-environmental conditions such as hypoxia, inflammation, or drug treatments (3) (4) (5) . MITF is part of a transcriptional program implemented by melanoma cells to switch from an invasive/mesenchymal status to a differentiated/fast-growing phenotype (6) . MITF silencing was also demonstrated to inhibit melanoma cell proliferation and to induce senescence (7, 8) .
A few years ago, a germline variant of MITF (p.E318K) was reported to predispose carriers to melanoma and kidney cancer (9, 10) . Using in vitro assays, we and others demonstrated that this mutation impairs MITF SUMOylation and affects the transcriptional activity of MITF. However, the mechanisms by which MITF E318K contributes to melanoma progression remain uncharacterized.
Senescence, a state of stable cell cycle arrest, is a tumor suppressor mechanism that is activated in response to oncogenic events (oncogene-induced senescence [OIS] ). One of the best examples of senescence in vivo is human nevus, a benign proliferation of cutaneous melanocytes and an early step in melanoma progression. Nevi frequently express oncogenic BRAF V600E and can remain growth-arrested for decades because of OIS (11, 12) , demonstrating that senescence provides an efficient suppression of cell proliferation. Primary melanoma can be viewed as a paradigm of senescence evasion, and the bypass of BRAF
V600E
-induced senescence triggers melanoma progression (13, 14) .
Here, we thought to evaluate the effect of the E318K mutation on endogenous MITF SUMOylation using proximity ligation assay (PLA). We also used a newly generated Mitf E318K knock-in 
Methods
Melanocytes were obtained from skin biopsies and were collected with participants' informed signed consent. Cells were transduced with an empty or BRAF V600E lentiviral particles.
Interactions between MITF and SUMO were detected by in situ proximity ligation assay (Sigma mice. which were genotyped and treated as described. For melanoma induction, we applied 1 ll of 4-hydroxytamoxifen (4-OHT, Sigma) 20 mM in EtOH on the back skin of mice (sex-matched mice) age three weeks for three consecutive days. Survival curves were determined using a Kaplan-Meier analysis using GraphPad Prism version 5 (GraphPad software, San Diego, CA) and are presented as survival days after 4-hydroxytamoxifen application (n ¼ 7 to 13 mice per group). Tumor samples were collected for RNA preparation.
Statistical Analysis
We used the t test to calculate 95% confidence intervals (CIs) on differences between means, and to obtain the P value we used GraphPad Prism and MedCalc (MedCalc Software's, Ostend, Belgium). All statistical tests were two-sided. For survival analysis, the Kaplan-Meier curves were performed with GraphPad Prism and the statistical analysis (median survival, CI, and P value) was performed with MedCalc. A P value of .05 or less was considered statistically significant when comparing the experimental and control groups.
Results

Study of Endogenous MITF E318K SUMOylation in Patients' Melanocytes
The MITF missense substitution p.E318K occurs in a consensus SUMOylation site. Furthermore, after overexpression of MITF and SUMO, we and others demonstrated that the mutation reduces MITF SUMOylation (9,10). However, these artifact conditions do not confirm that endogenous MITF SUMOylation is indeed affected. To remove this doubt, we used a proximity ligation assay (PLA) with anti-MITF and anti-SUMO antibodies. Experiments in melanocytes isolated from patients harboring the MITF E318K mutation revealed a dramatic decrease in the number of dots compared with melanocytes isolated from the skin of healthy donors, reflecting MITF hypo-SUMOylation in MITF E318K melanocytes ( Figure 1A ). Figure 2D ). Tumors from both groups exhibited comparable histological features with a spindle morphology as described above (Supplementary Figure 4D, Table 1 (available online) . Among the top activated biological functions associated with the genes differentially expressed, Ingenuity Pathway Analysis identified "Hematological System development" (P value range from .002 to < .001), and the annotations included "quantity of blood cells," "quantity of leukocytes," and "quantity of B lymphocytes," with a Z score between 1.66 and 2.48 (Supplementary Table 2 , available online). Indeed, Cd79a and Cd79b, which are known B cell markers, were among the most upregulated genes (Supplementary Table 1 Figure 2F ). Among them, the cyclin-dependent kinase inhibitors Cdkn2a (encoding both p16/Ink4A and p19Arf) and Cdkn2b play key roles in melanocyte senescence (18) . These observations suggest that MITF E318K might exert its pro-melanoma effect through an inhibition of oncogene-induced senescence. Figure 3C ). MITF E318K efficiently prevented the increase in SA-b-gal activity ( Figure 3B ) and the decrease in BrdU incorporation ( Figure 3C ) caused by BRAF
Effect of MITF
V600E
. Importantly, the level of both cell cycle inhibitors p21 and p16 was reduced in MITF E318K compared with wild-type MITF-expressing cells ( Figure 3A) . Consistent with these observations, expression of MITF E318K but not MITF impaired
-increased cell size and granularity, two additional senescence parameters (Supplementary Figure 6, A 
Discussion
SUMOylation is difficult to investigate given the dynamic and labile nature of this process. Forced expression of both the SUMO machinery and the target has been widely used to efficiently detect the SUMO-modified proteins, yet it may generate some unspecific SUMO conjugation. Detecting endogenous SUMOylation remains a challenge. Here, using PLA, we demonstrated for the first time the endogenous hypo-SUMOylated status of MITF E318K .
To establish the link between the MITF E318K melanoma susceptibility genes and pathogenesis mechanisms, we also constructed a new mouse model harboring the endogenous MITF E318K point mutation. In this model, we observed pigmentation lightening. Additionally, upon BRaf V600E/þ expression, our results reveal an increase in nevus count. Both observations were consistent with the phenotypes described in MITF
E318K
heterozygous patients (10, 20) . These data suggest that melanocytes expressing both BRAF V600E and MITF E318K can proliferate longer before entering senescence. This finding is reminiscent of patients with biallelic inactivation of the cell cycle inhibitor CDKN2A, which results in enhanced cell proliferation, who displays an increased number of nevi (21) . The decrease in pigmentation might be ascribed to impairment of the differentiation process. (9, 10) . Thus, we were unable to find the appropriate window to identify the MITF E318K targets, or MITF E318K might induce a weak effect on a large set of genes that cannot pass the statistical threshold. This is not surprising given that MITF E138K is not strongly oncogenic but rather a medium penetrance susceptibility allele. Furthermore, this finding is consistent with our ChIP-seq experiments demonstrating that MITF E318K is redistributed over the genome on a larger repertoire of low-affinity genomic sequence compared with wild-type MITF (9) . SUMOylation could induce a conformational change of MITF and impact the MITF interaction with its partner proteins. In addition, SUMO creates specific interactions with proteins containing SUMO-interacting motifs (SIMs) through a noncovalent bound. Therefore, the MITF E318K mutation will severely impair these interactions. Interestingly, the related family members TFE3 and TFEB (25, 26) are among the known MITF interactors. This interaction with MITF might be affected by the E318K mutation. Although the functional roles of MITF-TFE heterodimers in melanoma remain to be elucidated, it should be noted that TFE3 and TFEB are involved in kidney cancer (27) , the incidence of which is also increased in carriers of the MITF E318K mutation. Additionally, MITF interacts with the chromatin remodeler BRG1 (25, 28) ; thus, MITF could impact chromatin organization and global transcriptional regulation. Again, the MITF E318K mutation and the resulting SUMOylation alteration might affect the MITF interaction with BRG1, leading to the modification of the MITF target gene repertoire. This hypothesis is strengthened by the identification of a potential SUMOinteracting motif in BRG1 (GPS-SUMO, http://sumosp.biocuckoo. org/). However, only a small proportion of the available proteins typically needs to be SUMOylated to achieve a biological effect (29) . Because of this process, referred to as the "SUMO enigma," it has not been possible to identify such SUMO-dependent MITF interactors to date. This study has some limitations already mentioned above. First, we have not been able to identify specific MITF E318K target genes that could explain the effect of the mutation. To unmask such genes, we are currently evaluating the effect of Mitf E318K at early time points after the BRaf and Pten oncogenic activation. Second, due to the general scarcity and lability of SUMOylation, it has not been possible to identify changes in MITF E318K interactors that might mediate the pro-oncogenic effect of this mutation. An in vitro approach using recombinant SUMOylated or non-SUMOylated MITF and protein microarrays might solve this problem and disclose a direct molecular alteration caused by p.E318K mutation.
In conclusion, genetic association studies have been widely used in the search for cancer susceptibility genetic variants, but few studies have established the link between these variants and the pathogenesis mechanisms. This approach should allow important insights into the pathways of tumor development and might ultimately lead to more effective individually targeted cancer prevention strategies. Here, we characterized the alterations of MITF functions caused by the p.E318K mutation. Our results demonstrate that MITF E318K impaired the implementation of the senescence program and thus potentially favors melanoma progression.
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